Dongguan, China

Haoxiong Qin

USPTO Granted Patents = 2 

Average Co-Inventor Count = 6.2

ph-index = 1


Company Filing History:


Years Active: 2022-2025

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Haoxiong Qin: Innovator in Pharmaceutical Compounds

Introduction

Haoxiong Qin is a notable inventor based in Dongguan, China. He has made significant contributions to the field of pharmaceuticals, particularly in developing compounds that target inflammation and related diseases. With a total of 2 patents, his work is paving the way for new therapeutic options.

Latest Patents

Qin's latest patents include two innovative compounds. The first patent is for an isoquinolinone compound that acts as an inhibitor of semicarbazide-sensitive oxidase (SSAO) and vascular adhesion protein-1 (VAP-1). This compound is particularly useful in preparing drugs aimed at preventing, treating, or ameliorating inflammation and diabetes-related diseases, including non-alcoholic fatty liver diseases. The second patent involves an amine compound that serves as an SSAO and VAP-1 inhibitor. This compound is also designed for use in pharmaceutical compositions that can treat a variety of conditions, including psychiatric disorders and ischemic diseases.

Career Highlights

Haoxiong Qin is currently associated with Sunshine Lake Pharma Co., Ltd., where he continues to innovate in the pharmaceutical sector. His work is characterized by a strong focus on developing compounds that address critical health issues.

Collaborations

Qin collaborates with esteemed colleagues, including Zheng Gu and Jianhao Li, to further enhance the impact of his research and inventions.

Conclusion

Haoxiong Qin's contributions to pharmaceutical innovations are significant, particularly in the development of compounds that target inflammation and related diseases. His work exemplifies the importance of research and innovation in improving health outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…